APGE
NASDAQ HealthcareApogee Therapeutics, Inc. - Common Stock
Biotechnology
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
�� 市场数据
| 价格 | $92.20 |
|---|---|
| 成交量 | 1,077,764 |
| 市值 | 6.88B |
| 贝塔系数 | 1.020 |
| RSI（14日） | 91.5 超买 |
| 200日均线 | $59.50 |
| 50日均线 | $74.81 |
| 52周最高 | $95.31 |
| 52周最低 | $32.36 |
| Forward P/E | -16.89 |
| Price / Book | 6.98 |
🎯 投资策略评分
APGE 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (95/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 APGE in your text
粘贴任何文章、记录或帖子 — 工具将提取 APGE 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.